American Regent, Inc.
One Luitpold Drive
P.O. Box 9001
44 articles about American Regent, Inc.
American Regent, Inc., a Daiichi Sankyo Group company, announced results from the phase 3 HEART-FID trial of INJECTAFER® for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction.
American Regent announces the launch of sulfite-free Epinephrine Injection, USP.
American Regent, Inc. and Provepharm Life Solutions are pleased to announce the availability of ProvayBlue® Injection, USP in a 10 mL single-dose vial.
American Regent announces the launch of Selenious Acid Injection, USP in a 12 mcg/2 mL single-dose vial.
American Regent, Inc. is pleased to announce the launch of Selenious Acid Injection, USP in a new concentration and vial size.
American Regent announces the introduction and availability of FDA-approved Vasopressin Injection, USP.
Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for the Treatment of Pediatric Patients with Iron Deficiency Anemia
Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved Injectafer for pediatric patients (who are 1 year of age or older) with iron deficiency anemia (IDA) who are intolerant to oral iron or who have had an unsatisfactory response to oral iron.
American Regent, Inc., a Daiichi Sankyo Group company, announced that Ken Keller, currently serving as the company's President and CEO, is transitioning to a new role as the Global Head of Oncology Business at Daiichi Sankyo, Inc. effective April 1, 2021.
American Regent Inc Selects Sparta Systems' TrackWise Digital QMS to Seamlessly Connect Quality Across Manufacturing, Clinical and Supplier Network
Today, Sparta Systems, Inc., the leading provider of quality management solutions for life sciences, announced that American Regent, Inc., a top-10 injectable manufacturer, has chosen TrackWise Digital® as its next generation cloud platform for manufacturing, clinical, and supplier management.
American Regent Introduces Estradiol Valerate Injection, USP; AO Rated and Therapeutically Equivalent to Delestrogen®1, 2
American Regent announces the introduction and availability of Estradiol Valerate Injection, USP – AO Rated and therapeutically equivalent to Delestrogen®
American Regent Introduces niCARdipine Hydrochloride Injection, USP; AP Rated and Therapeutically Equivalent to Cardene® (1, 2)
American Regent announced the introduction of the only FDA approved USP standard Nicardipine Hydrochloride Injection. Nicardipine Hydrochloride is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible.
The company manufactures 99% of its medications in the United States, allowing it to reliably and quickly supply high-quality, life-saving treatments to those in need.
American Regent, Inc. to Acquire a Daiichi Sankyo Affiliate API Manufacturing Facility in France to Complement Its U.S. Manufacturing
American Regent, Inc., a U.S. manufacturer of pharmaceuticals for human and veterinary use with manufacturing sites in New York and Ohio , announced today that it will acquire Daiichi Sankyo Altkirch SARL, a Daiichi Sankyo company that has an Active Pharmaceutical Ingredient (API) pharmaceutical manufacturing plant in Altkirch, F
American Regent, Inc., a manufacturer and distributor of pharmaceuticals that addresses diverse medical and veterinary needs, announced that it has moved its corporate offices to Melville, New York.
American Regent, Inc. announced the introduction of FDA approved Zinc Sulfate Injection, USP.
American Regent Announces the Re-Introduction of Aminocaproic Acid Injection, USP; AP Rated and Therapeutically Equivalent to Amicar®*(1)
American Regent announced the re-introduction of Aminocaproic Acid Injection, USP, a therapeutically equivalent generic alternative to Amicar®.
American Regent Re-introduces Droperidol Injection, USP; AP Rated and Therapeutically Equivalent to Inapsine®1*
American Regent, Inc. announced the re-introduction of Droperidol Injection, USP.
Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
Amneal Pharmaceuticals, Inc. today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena®
American Regent, Inc. Announces Enrollment Of First Patient In Phase III Trial To Investigate Injectafer (Ferric Carboxymaltose) As Treatment For Heart Failure With Iron Deficiency
American Regent, Inc.'s Injectafer® (Ferric Carboxymaltose Injection) Assigned J Code By Centers For Medicare & Medicaid Services